August 2011
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6
Trade Publication
The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.


Related Articles

  • Pharma: Other News To Note.  // BioWorld Today;10/1/2013, Vol. 24 Issue 188, p15 

    This section offers news briefs related to pharmaceutical industry including the approval of UCB SA's Cimzia drug for psoriatic arthritis, and the plan of Vansen Pharma Inc. to offer its shares under a ticker symbol VNSN.

  • COMPANY SPOTLIGHT - UCB.  // PharmaWatch: CNS;Dec2007, Vol. 6 Issue 12, p14 

    The article profiles UCB, a global biopharmaceutical company engaged in the research, development and commercialization of pharmaceutical and biotechnology products. It is said that in the epilepsy therapeutic category, the company markets brands such as Keppra and Nootropil. Moreover, for...

  • DATAMONITOR: UCB S.A.  // UCB SA SWOT Analysis;Jul2009, p1 

    The article presents a corporate profile of Brussels, Belgium-based biopharmaceutical company UCB SA. It offers details on the company's financial performance as of December 2008, business operations, markets, contact information and number of employees. An analysis of the company's strengths,...

  • Eat or Be Eaten. Doliveux, Roch // Pharmaceutical Executive;Aug2006, Vol. 26 Issue 8, p96 

    The article presents a perspective on the developments surrounding UCB. The initials UCB originally stood for Union Chimique Beige. Few years ago, sales were 50 percent pharmaceuticals, 50 percent chemicals. About 85 percent of our profits came from pharmaceuticals, and only 15 percent from...

  • Dr. Reddy's to acquire select products of Belgian firm, UCB.  // FRPT- Chemical Snapshot;4/19/2015, p14 

    The article reports that Dr. Reddy's Laboratories will purchase some products of biopharmaceutical firm UCB in Maldives, Sri Lanka, Nepal and India in April 2015.

  • FURTHER READING.  // PharmaWatch: CNS;Nov2011, Vol. 10 Issue 11, p27 

    The article lists the latest reports in the U.S. pharmaceutical industry which include drugs for the treatment of Scizophrenia, overview of neuropathic pain definitions in HIV, diabetes, and herpes zoster, and company profile of UCB SA.

  • Kremers Urban Pharmaceuticals Inc.  // Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p78 

    The article profiles Kremers Urban Pharmaceuticals Inc., a subsidiary of Belgium-base UCB SA, which focuses on delivering product solutions and customer service with a commitment to improve products that are needed to get generic products to the U.S. market.

  • Epilepsy Update.  // PharmaWatch: CNS;Mar2006, Vol. 5 Issue 3, p6 

    The article reports on developments about drugs for treating epilepsy. The U.S. Food and Drug Administration has requested more information before approving the intravenous version of UCB SA's Keppra drug. Keppra was also recommended for approval by an advisory committee to the European...

  • UCB: continuing the European Mid-Pharma consolidation craze.  // PharmaWatch: CNS;Nov2006, Vol. 5 Issue 11, p4 

    The article reports that an offer of E4.4 billion has been made by UCB SA for Schwarz Pharma AG, a pharmaceutical company. The new company is expected to specialize in neurology along with the therapeutic areas of oncology and inflammation. Small molecule therapies is one of the specialized...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics